Walking Pneumonia: Causes and Trends

What is Triple-Negative Breast Cancer (TNBC)?

• A type of breast cancer that lacks estrogen, progesterone, and HER2 receptors.
• A cancer that is positive for estrogen, progesterone, and HER2 receptors.
• A type of cancer found only in older women.
• A form of breast cancer that only occurs in men.

Which of the following is a common treatment side effect of chemotherapy for Triple-Negative Breast Cancer?

• Loss of appetite.
• Hair loss.
• Fatigue.
• Increased appetite.

What is the importance of early detection in Triple-Negative Breast Cancer?

• It reduces the need for chemotherapy.
• It is critical for improving survival rates.
• Early detection increases the chances of successful treatment.
• It prevents the cancer from spreading.

What is a key factor in determining the prognosis of someone with Triple-Negative Breast Cancer?

• Size of the tumor.
• Stage at diagnosis.
• Age of the patient.
• Whether they have surgery.

What is a common treatment option for Triple-Negative Breast Cancer?

• Hormone therapy.
• HER2-targeted therapy.
• Chemotherapy.
• Immunotherapy.

Which group has a higher risk of developing Triple-Negative Breast Cancer?

• Older women.
• African American women.
• Asian women.
• Hispanic women.

What does the "negative" in Triple-Negative refer to?

• The lack of estrogen, progesterone, and HER2 receptors.
• The presence of certain genes.
• The negative response to chemotherapy.
• The inability to spread.

Which of the following is NOT typically used to treat Triple-Negative Breast Cancer?

• Chemotherapy.
• Hormone therapy.
• Radiation therapy.
• Surgery.

Which genetic mutation is most often associated with an increased risk for TNBC?

• BRCA1 mutation.
• BRCA2 mutation.
• P53 mutation.
• KRAS mutation.

What role do clinical trials play in the treatment of Triple-Negative Breast Cancer?

• They are only used for research purposes.
• Clinical trials offer access to new treatments and therapies.
• They have no impact on treatment decisions.
• Clinical trials are limited to later stages.

What is one of the key concerns with chemotherapy for Triple-Negative Breast Cancer?

• It can target specific receptors.
• It has fewer side effects than other treatments.
• It can cause serious side effects and long-term health issues.
• It works well for all stages.

What is the survival rate for Triple-Negative Breast Cancer compared to other types?

• Lower survival rate.
• Similar to other types.
• Higher survival rate.
• No difference.

What is the most common symptom of Triple-Negative Breast Cancer?

• Pain in the breast.
• Swelling in the breast.
• A lump in the breast.
• Discharge from the nipple.

Which of the following is true about the genetic factors associated with Triple-Negative Breast Cancer?

• Mutations in BRCA1 are linked to a higher risk.
• BRCA mutations are not relevant.
• Genetic testing is not recommended for TNBC.
• TNBC is always inherited.

At what age is Triple-Negative Breast Cancer most commonly diagnosed?

• Under 40 years old.
• Between 40-60 years old.
• Over 60 years old.
• Any age.

What is one reason why Triple-Negative Breast Cancer is more aggressive than other forms?

• It tends to grow and spread more quickly.
• It has higher levels of estrogen.
• It is less likely to metastasize.
• It responds well to treatment.

What does the term "HER2" stand for in breast cancer?

• Human Epidermal Growth Factor Receptor 2.
• Human Epidermal Growth Factor Receptor.
• Hereditary Estrogen Receptor.
• Hormonal Estrogen Response.

Which of the following is associated with a better prognosis for TNBC?

• Advanced stage.
• Early detection.
• Tumor size larger than 5 cm.
• Lack of chemotherapy.

Which of the following is a common side effect of chemotherapy for Triple-Negative Breast Cancer?

• Nausea and vomiting.
• Sore throat.
• Weight gain.
• Increased skin pigmentation.

What role does the BRCA1 gene mutation play in the risk of Triple-Negative Breast Cancer?

• It increases the risk of developing TNBC.
• It decreases the risk of TNBC.
• It has no effect on the risk.
• It only affects the treatment options.

Can Triple-Negative Breast Cancer spread to other parts of the body?

• No, it only stays in the breast.
• Yes, it can spread to the lungs and liver.
• Yes, it can spread to other organs including the lungs, liver, and brain.
• No, it remains localized to the breast area.

Which treatment is most commonly used after surgery for Triple-Negative Breast Cancer?

• Chemotherapy.
• Radiation therapy.
• Immunotherapy.
• Hormone therapy.

Which of the following is a potential benefit of participating in a clinical trial for Triple-Negative Breast Cancer?

• Access to new therapies that may be more effective.
• Potential to benefit from new experimental treatments.
• Opportunity to avoid chemotherapy.
• More chances of survival with no treatment.

How does the absence of estrogen and progesterone receptors impact treatment for Triple-Negative Breast Cancer?

• It limits the use of hormone therapy.
• It makes chemotherapy more effective.
• It increases survival rates.
• It allows for targeted therapies to work better.

What is the role of chemotherapy in treating Triple-Negative Breast Cancer?

• Chemotherapy is the primary treatment for TNBC.
• Chemotherapy is used only after surgery.
• Chemotherapy is not effective for TNBC.
• Chemotherapy is used for advanced TNBC only.

What is the most common imaging technique used to detect Triple-Negative Breast Cancer?

• Mammography.
• MRI.
• Ultrasound.
• CT scan.

Which of the following is a risk factor for Triple-Negative Breast Cancer?

• Family history of breast cancer.
• Low-fat diet.
• High physical activity.
• Low estrogen exposure.

What is the function of HER2 receptors in breast cancer cells?

• To bind to estrogen and progesterone.
• To make breast cancer cells less aggressive.
• To promote cancer cell growth in HER2-positive cancers.
• To reduce tumor size.

Which treatment option is NOT typically used for Triple-Negative Breast Cancer?

• Surgery.
• Hormone therapy.
• Chemotherapy.
• Radiation.

What is a major limitation of using chemotherapy alone for Triple-Negative Breast Cancer?

• Chemotherapy is ineffective for TNBC.
• Chemotherapy can cause resistance in TNBC cells.
• Chemotherapy alone has a lower success rate compared to combined treatments.
• Chemotherapy cannot target HER2 receptors.

What is the role of surgery in treating Triple-Negative Breast Cancer?

• Surgery is often used to remove the tumor.
• Surgery is only done for advanced stages.
• Surgery is used after chemotherapy.
• Surgery is not typically used.

What is a key reason why Triple-Negative Breast Cancer tends to be more difficult to treat?

• It is less likely to spread.
• It responds well to radiation therapy.
• Lack of targeted therapies and hormonal treatments.
• It grows slowly.

What is the general treatment approach for Triple-Negative Breast Cancer?

• Hormone therapy.
• Immunotherapy.
• Surgery, chemotherapy, and radiation.
• Only chemotherapy.

Which of the following can increase the risk of developing Triple-Negative Breast Cancer?

• Inherited BRCA mutations.
• High-fat diet.
• Regular exercise.
• Low estrogen exposure.

What is one of the primary reasons chemotherapy is often used for Triple-Negative Breast Cancer?

• It is the most effective treatment.
• It targets estrogen receptors.
• It is one of the most effective treatments available for TNBC.
• It works well in all stages.

What is the likelihood of recurrence for Triple-Negative Breast Cancer?

• High in the first 3 years after treatment.
• Low recurrence rate.
• Higher recurrence rate, especially within the first 5 years.
• Recurrence is rare.

Which of the following is NOT a typical symptom of Triple-Negative Breast Cancer?

• Lump in the breast.
• Pain in the breast.
• Sudden weight loss without cause.
• Swelling of the breast.

What does the "negative" in Triple-Negative Breast Cancer mean in terms of receptor status?

• The absence of cancer cells.
• The lack of a strong immune response.
• The absence of estrogen, progesterone, and HER2 receptors.
• The lack of lymph node involvement.

What percentage of breast cancers are classified as Triple-Negative?

• 10-20%
• 30-40%
• 50-60%
• 70-80%

Which of the following is a common chemotherapy drug used for Triple-Negative Breast Cancer?

• Tamoxifen.
• Taxanes (like paclitaxel).
• Herceptin.
• Aromatase inhibitors.

What does "triple-negative" refer to in TNBC?

• The absence of estrogen receptors, progesterone receptors, and HER2 protein.
• Only the lack of estrogen receptors.
• The presence of progesterone and HER2 receptors.
• The presence of cancer cells in the lymph nodes.

What does the "triple" in Triple-Negative Breast Cancer refer to?

• Lack of estrogen, progesterone, and HER2 receptors.
• The three stages of cancer.
• The number of cancerous lymph nodes.
• The type of chemotherapy used.

What is the role of radiation therapy in the treatment of Triple-Negative Breast Cancer?

• It is used to shrink tumors before surgery.
• It is often used after surgery to reduce the risk of recurrence.
• It is used in advanced stages only.
• It is not typically recommended.

How is Triple-Negative Breast Cancer different from other types of breast cancer?

• It is more responsive to hormone therapy.
• It has higher HER2 expression.
• It lacks estrogen, progesterone, and HER2 receptors.
• It has a better survival rate.

What is the survival outlook for women diagnosed with early-stage Triple-Negative Breast Cancer?

• Better compared to those diagnosed at later stages.
• Similar to other types of breast cancer.
• Worse than other types of breast cancer.
• Less dependent on stage of diagnosis.

Which ethnic group is at higher risk for Triple-Negative Breast Cancer?

• Caucasians.
• Asians.
• African Americans.
• Latinas.

Which of the following is a challenge in treating Triple-Negative Breast Cancer?

• Lack of effective treatments.
• Lack of targeted therapies.
• Poor prognosis.
• All of the above.

What is the role of immunotherapy in treating Triple-Negative Breast Cancer?

• It is the first-line treatment.
• Immunotherapy is a newer treatment option for advanced cases.
• It has no effect on TNBC.
• It is only used after chemotherapy.

What is the primary reason for the aggressive nature of Triple-Negative Breast Cancer?

• Lack of effective treatment options.
• It is linked to genetic mutations.
• It spreads slowly.
• It responds well to chemotherapy.

What is the primary challenge with the lack of hormone receptors in Triple-Negative Breast Cancer?

• Lack of estrogen.
• Lack of targeted treatment options.
• Lack of chemotherapy options.
• Lack of radiation response.